BridgeBio, BMS to develop and commercialize SHP2 inhibitor BBP-398

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

BridgeBio Pharma and Bristol Myers Squibb announced an exclusive license to develop and commercialize BBP-398, an SHP2 inhibitor, in oncology.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Login